CRISPR Therapeutics Shares Rise Nearly 19% in August on Strong Earnings and Business Update
In early August 2026, CRISPR Therapeutics (NASDAQ: CRSP) reported strong second-quarter financial results that contributed to a nearly 19% rise in its stock price. The company's revenue surged from $892,000 in the same period of 2025 to over $10.2 million due largely to an undisclosed $10 million upfront payment under a licensing and collaboration deal. CRISPR’s only approved product, Casgevy (developed with Vertex Pharmaceuticals), saw sales jump by 78% quarter-over-quarter to $76 million. Additionally, the U.S. Food and Drug Administration expanded approval for Casgevy to include pediatric patients aged two and older. Despite not recognizing its share of Casgevy’s revenue directly as income due to partnership terms, CRISPR reported a significant reduction in net loss compared to last year. The company continues developing new therapies using its gene-editing platform, targeting conditions like hypertension and alpha-1 antitrypsin deficiency.
Topics: biotech earnings_report FDA_approval